Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Peginterferon beta-1a is used for relapsing multiple sclerosis (MS).
• Injection site reactions (ISRs) and flu-like symptoms (FLS) are common adverse events.
• These adverse events can lead to treatment discontinuation.

Purpose of the Study:

• To explore peginterferon beta-1a discontinuation rates in MS.
• To reach consensus on ISR and FLS management strategies.
• To identify needs for nurse and patient education to improve outcomes.

Main Methods:

• Modified Delphi process involving international MS-certified nurses.
• Two survey rounds completed by 262 and 188 nurses across nine countries.
• Exploration of discontinuation rates and management strategies.

Main Results:

• Nurses reported 25% ISRs and 30% FLS with peginterferon beta-1a.
• Discontinuation was highest within the first 6 months; follow-ups were often at 6 months.
• Preferred management included NSAIDs/site rotation for ISRs and acetaminophen/hydration for FLS.
• 77% of nurses desired more education on ISR/FLS management.

Conclusions:

• Consensus was achieved on ISR and FLS management strategies.
• Improved management can inform treatment decisions for MS patients.
• More frequent follow-ups and individualized education are recommended to enhance ISR/FLS management.